周力,孙颖,陈晖

• 1:首都医科大学附属北京友谊医院医疗保健中心
• 2:首都医科大学附属北京友谊医院心脏中心

摘要(Abstract)：

<正>冠心病介入治疗技术在近30年间挽救了数以万计患者,其从最初的单纯球囊扩张,到20世纪90年代裸金属支架的问世,以至目前临床上广泛应用的药物洗脱支架(DES),已经历了3次历史性革命。但是以不锈钢和钴铬合金为基础的DES仍不能从根本上解决支架内血栓形成和再狭窄的问题。介入心脏病学专家梦想着支架在完成支撑血管的作用后能够消失,避免让金属支架永久留在患者体内。临床实践的要求催生器械的进步,全吸收式生物可降解支架应运而生。

关键词(KeyWords)： 全吸收式生物可降解支架;冠心病介入治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 周力,孙颖,陈晖

参考文献(References)：

• [1]Tsuji T,Tamai H,Igaki K,et al.One year follow-up biodegradable self-expanding stent implantation in humans.J AmColl Cardiol,2001,37:A47.
• [2]Erbel R,Di Mario C,Bartunek J,et al.Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents:a prospective,non-randomised multicentre trial.Lancet,2007,369:1869-1875.
• [3]Ghimire G,Spiro J,Kharbanda R,et al.Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents.Euro Intervention,2009,4:481-484.
• [4]Waksman R,Erbel R,Di Mario C,et al.Early-and longtermintravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries.J Am Coll Cardiol Intv,2009,2:312-320.
• [5]Ormiston JA,Serruys PW,Regar E,et al.A bioabsorbable everolimus-eluting coronary stent system for patients with single denovo coronary artery lesions(ABSORB):a prospective open-label trial.Lancet,2008,371:899-907.
• [6]Dudek D,Onuma Y,Ormiston JA,et al.Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease:the ABSORB trial.EuroIntervention,2012,7:1060-1061.
• [7]Onuma Y,Serruys PW,Gomez J,et al.Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds(revision 1.0 and 1.1)and the metallic everolimus-eluting stent.Catheter Cardiovasc Interv,2011,78:3-12.
• [8]Ormiston JA,Serruys PW,Onuma Y,et al.First serial assessment at6 months and 2 years of the second generation of absorb everolimuseluting bioresorbable vascular scaffold:a multi-imaging modality study.Circ Cardiovasc Interv,2012,5:620-632.
• [9]Serruys PW,Onuma Y,Dudek D,et al.Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis:12-month clinical and imaging outcomes.J Am Coll Cardiol,2011,58:1578-1588.
• [10]Brugaletta S,Radu MD,Garcia-Garcia HM,et al.Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation:can the scaffold cap the plaque?Atherosclerosis,2012,221:106-112.
• [11]Brugaletta S,Heo JH,Garcia-Garcia HM,et al.Endothelialdependent vasomotion in a coro nary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer:indirect fi nding of vascular reparative therapy?Eur Heart J,2012,33:1325-1333.
• [12]Muramatsu T,Onuma Y,García-García HM,et al.Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold:an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT fi rst and II trials.J Am Coll Cardiol Intv,2013,6:247-257.
• [13]Dzavík V,Colombo A.The Absorb Bioresorbable vascular scaffold in coronary bifurcations.J Am Coll Cardiol Intv,2014,7:81-88.